Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Manzanita Pharmaceuticals Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are distributed across 2 distinct examiners. MIKNIS, ZACHARY J is the busiest examiner, holding 1 pending office action.
The distribution of 2 pending office actions across 2 distinct art units indicates a range of technical classifications within the portfolio. Because the busiest examiner pending count is 1, the workload is shared between 2 distinct examiners. This distribution allows for a comparison of prosecution results across the 2 distinct art units. Practitioners may find that having different examiners for the pending workload provides various perspectives on the company's technologies. The presence of 2 distinct art units suggests that the company's filings are not limited to a specific specialized group.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
| SCHLIENTZ, LEAH H | 1 | 41.8% | +38.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769693 | NEUROTROPHIN RECEPTOR BINDING CONJUGATE COMPOSITIONS, METHODS OF USE AND METHODS OF MAKING THEREOF | SCHLIENTZ, LEAH H | 23d |
| 18039126 | METHODS FOR USING NEUROTROPHIN RECEPTOR BINDING CONJUGATE COMPOSITIONS IN THE TREATMENT OF A NEUROLOGICAL CONDITION | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18039126 | METHODS FOR USING NEUROTROPHIN RECEPTOR BINDING CONJUGATE COMPOSITIONS IN THE TREATMENT OF A NEUROLOGICAL CONDITION | MIKNIS, ZACHARY J | 1658 | §112 | Non-Final OA | — | Pending | May 26, 2023 |
| 17769693 | NEUROTROPHIN RECEPTOR BINDING CONJUGATE COMPOSITIONS, METHODS OF USE AND METHODS OF MAKING THEREOF | SCHLIENTZ, LEAH H | 1618 | §102 | Final Rejection | 23d | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialManzanita Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Zachary J Miknis has the most, with 1 of Manzanita Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
